Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claire Roddie

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Leukemia|April 1, 2025
Site-specific analysis of extranodal involvement in large B-cell lymphoma reveals distinct efficacy with chimeric antigen receptor T-cell therapyGloria Iacoboni, Kai Rejeski, Víctor Navarro, et al.
Blood|February 23, 2023
Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphomaClaire Roddie, Lazaros J Lekakis, Maria A V Marzolini, et al.
Science Translational Medicine|July 1, 2026
CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosisAlexandros Rampotas, Zoë C Wong, Isaac Gannon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2021
Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic LeukemiaClaire Roddie, Juliana Dias, Maeve A O'Reilly, et al.
Blood|September 6, 2018
RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signatureMichael A Chapman, Jonathan Sive, John Ambrose, et al.
Blood Advances|March 27, 2026
Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphomaAndrea Kuhnl, Amy A Kirkwood, Michael Northend, et al.
Journal of Hepatology|August 14, 2025
Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinomaTim Meyer, Richard S Finn, Mitesh Borad, et al.
Cancer Cell|March 27, 2018
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 AntibodiesFrederick Arce Vargas, Andrew J S Furness, Kevin Litchfield, et al.
The New England Journal of Medicine|November 27, 2024
Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic LeukemiaClaire Roddie, Karamjeet S Sandhu, Eleni Tholouli, et al.
Blood Cancer Journal|April 15, 2024
Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access schemeMacarena Oporto Espuelas, Saskia Burridge, Amy A Kirkwood, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Leukemia|April 1, 2025
Site-specific analysis of extranodal involvement in large B-cell lymphoma reveals distinct efficacy with chimeric antigen receptor T-cell therapyGloria Iacoboni, Kai Rejeski, Víctor Navarro, et al.
Blood|February 23, 2023
Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphomaClaire Roddie, Lazaros J Lekakis, Maria A V Marzolini, et al.
Science Translational Medicine|July 1, 2026
CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosisAlexandros Rampotas, Zoë C Wong, Isaac Gannon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2021
Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic LeukemiaClaire Roddie, Juliana Dias, Maeve A O'Reilly, et al.
Blood|September 6, 2018
RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signatureMichael A Chapman, Jonathan Sive, John Ambrose, et al.
Blood Advances|March 27, 2026
Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphomaAndrea Kuhnl, Amy A Kirkwood, Michael Northend, et al.
Journal of Hepatology|August 14, 2025
Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinomaTim Meyer, Richard S Finn, Mitesh Borad, et al.
Cancer Cell|March 27, 2018
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 AntibodiesFrederick Arce Vargas, Andrew J S Furness, Kevin Litchfield, et al.
The New England Journal of Medicine|November 27, 2024
Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic LeukemiaClaire Roddie, Karamjeet S Sandhu, Eleni Tholouli, et al.
Blood Cancer Journal|April 15, 2024
Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access schemeMacarena Oporto Espuelas, Saskia Burridge, Amy A Kirkwood, et al.
Pageof 7